INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
(WorldNews Health)

INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events Late-breaking study shows improved renal and heart failure outcomes also seen with INVOKANAin both of these patient groups RARITAN, N.J.and ANAHEIM, Calif.,November 14, 2017 - Janssen Research & Development, LLC (Janssen) today announced a new analysis from the CANVAS Program, which showed INVOKANA (canagliflozin) demonstrated a reduced risk of cardiovascular (CV) outcomes in patients with and without a history of CV disease. INVOKANA also achieved similar and proportional risk reductions for hospitalization due to heart failure (HHF) and renal...